Vol 69, No 12 (2011)
Original articles
Published online: 2011-12-15
Surgical ablation for atrial fibrillation using the Ex−Maze III procedure on the beating heart in patients undergoing mitral valve surgery
DOI: 10.33963/v.kp.79446
Kardiol Pol 2011;69(12):1228-1232.
Abstract
Background: The Ex-Maze III procedure is a recently developed surgical method for ablation of atrial fibrillation (AF). The
procedure uses epicardial approach and can be performed on the beating heart.
Aim: To evaluate the efficacy and safety of Ex-Maze III ablation in patients undergoing mitral valve (MV) surgery.
Methods: The study group consisted of 20 consecutive patients (8 males, mean age 67 years) who underwent MV surgery and had concomitant AF. Eighteen patients were diagnosed with long-standing permanent AF and 2 patients with paroxysmal AF. The mean duration of AF was 9.5 years prior to surgery. All the patients underwent the Ex-Maze III procedure on the beating heart immediately before the MV surgery (MV replacement in 17 patients and MV repair in 3 patients). The patients were followed 1, 3, 6 and 12 months after procedure with ECG and 24-h ambulatory ECG monitoring (at 12 months).
Results: There were no serious complications in the study group. All the patients were in AF immediately after the procedure and underwent electrical or pharmacological cardioversion (4 and 16 patients, respectively). The proportion of patients remaining in sinus rhythm was 15 (75%) patients at 1 month, 16 (80%) patients at 3 months, 17 (85%) patients at 6 months and 12 months after procedure.
Conclusions: The Ex-Maze III procedure for ablation of AF on the beating heart is safe and effective in patients with AF undergoing concomitant MV surgery. In order to better evaluate the outcomes of the procedure a prospective randomised multicentre study is needed.
Kardiol Pol 2011; 69, 12: 1228–1232
Aim: To evaluate the efficacy and safety of Ex-Maze III ablation in patients undergoing mitral valve (MV) surgery.
Methods: The study group consisted of 20 consecutive patients (8 males, mean age 67 years) who underwent MV surgery and had concomitant AF. Eighteen patients were diagnosed with long-standing permanent AF and 2 patients with paroxysmal AF. The mean duration of AF was 9.5 years prior to surgery. All the patients underwent the Ex-Maze III procedure on the beating heart immediately before the MV surgery (MV replacement in 17 patients and MV repair in 3 patients). The patients were followed 1, 3, 6 and 12 months after procedure with ECG and 24-h ambulatory ECG monitoring (at 12 months).
Results: There were no serious complications in the study group. All the patients were in AF immediately after the procedure and underwent electrical or pharmacological cardioversion (4 and 16 patients, respectively). The proportion of patients remaining in sinus rhythm was 15 (75%) patients at 1 month, 16 (80%) patients at 3 months, 17 (85%) patients at 6 months and 12 months after procedure.
Conclusions: The Ex-Maze III procedure for ablation of AF on the beating heart is safe and effective in patients with AF undergoing concomitant MV surgery. In order to better evaluate the outcomes of the procedure a prospective randomised multicentre study is needed.
Kardiol Pol 2011; 69, 12: 1228–1232
Keywords: atrial fibrillationablationEx-Maze III
